Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation

PLoS One. 2012;7(10):e47808. doi: 10.1371/journal.pone.0047808. Epub 2012 Oct 19.

Abstract

Background: Hepatitis B virus (HBV) infection remains a severe public health problem. Investigating its prevalence and trends is essential to prevention.

Methods: To evaluate the effectiveness of HBV vaccination under the 1992 Intervention Program for infants and predicted HBV prevalence trends under the 2011 Program for all ages. We conducted a community-based investigation of 761,544 residents of 12 counties in Zhejiang Province selected according to their location, population density, and economic development. The HBV prevalence trends were predicted by a time-shifting approach. HBV surface antigen (HBsAg) and alanine amino transferase (ALT) were determined.

Results: Of the 761,544 persons screened for HBsAg, 54,132 were positive (adjusted carrier rate 6.13%); 9,455 had both elevated ALT and a positive HBsAg test (standardized rate 1.18%). The standardized HBsAg carrier rate for persons aged ≤20 years was 1.51%. Key factors influencing HBV infection were sex, age, family history, drinking, smoking, employment as a migrant worker, and occupation. With the vaccination program implemented in 2011, we predict that by 2020, the HBsAg carrier rate will be 5.27% and that for individuals aged ≤34 years will reach the 2% upper limit of low prevalence according to the WHO criteria, with a standardized rate of 1.86%.

Conclusions: The national HBV vaccination program for infants implemented in 1992 has greatly reduced the prevalence of HBV infection. The 2011 program is likely to reduce HBV infection in Zhejiang Province to a low moderate prevalence, and perinatal transmission is expected to be controlled by 2020.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Alanine Transaminase / blood*
  • Biomarkers / blood
  • Carrier State / immunology
  • Carrier State / prevention & control*
  • Carrier State / virology
  • Child
  • Child, Preschool
  • China / epidemiology
  • Female
  • Forecasting
  • Hepatitis B Surface Antigens / blood*
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / immunology*
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / immunology
  • Hepatitis B, Chronic / prevention & control*
  • Hepatitis B, Chronic / virology
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Prevalence
  • Sex Factors
  • Vaccination*

Substances

  • Biomarkers
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Alanine Transaminase

Grants and funding

This study was supported in part by grants from the Mega-Project for National Science and Technology Development under the “11th and 12th Five-Year Plan of China” (2009ZX10004-901, 2011ZX10004-901), the National Science and Technology Support Program of “11th Five-Year Plan” (2008BAH27B00), and the National Natural Science Foundation of China (81001271). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.